Forbion Capital Partners announced the first and final closing of its second FCF 1 Co-Investment Fund at approximately $50 million.
The fund aims to invest additional capital, alongside its existing funds, in several late stage FCF 1 portfolio companies that are close to an exit. Forbion’s first FCF 1 Co-Investment Fund of $72m closed in September 2010, and has made six investments to date, two of which have already been sold, repaying the entire fund up to two times.
These exits include Biovex, sold to Amgen in January 2011 for up to $1billion and Pathway Medical, sold in September 2011 to Bayer MedRad for $125m. In both companies, Forbion was the largest investor.
Based on these successes and the promise of further high quality assets in FCF 1, its limited partners have committed to Forbion’s FCF 1 Co-Investment Fund 2.
The new FCF 1 Co-Investment Fund has already made its first investment in Circulite, Inc., announced earlier this month. Martien van Osch, managing partner at Forbion responsible for the Circulite investment said that having access to this additional pool of capital allowed Forbion to strongly support Circulite in the funding round.
Release Date: Dec. 8, 2011
Source: Forbion Capital Partners